DeepCure
DeepCure discovers and develops novel small-molecule therapies for immune and inflammatory diseases using AI to shorten the drug discovery timeline. The company operates a B2B SaaS-style drug discovery platform called Inspired Chemistry that combines deep learning, reinforcement learning, physics-based modeling and automated chemical synthesis to design, optimize and produce testable compounds. Its technology stack includes artificial intelligence and machine learning models integrated with automated synthesis workflows and advanced in silico chemistry tools. DeepCure works with biopharma partners and research institutions and has progressed multiple preclinical candidates, including selective BRD4(BD2) and STAT6 inhibitors, toward IND-enabling studies.
DeepCure
DeepCure discovers and develops novel small-molecule therapies for immune and inflammatory diseases using AI to shorten the drug discovery timeline. The company operates a B2B SaaS-style drug discovery platform called Inspired Chemistry that combines deep learning, reinforcement learning, physics-based modeling and automated chemical synthesis to design, optimize and produce testable compounds. Its technology stack includes artificial intelligence and machine learning models integrated with automated synthesis workflows and advanced in silico chemistry tools. DeepCure works with biopharma partners and research institutions and has progressed multiple preclinical candidates, including selective BRD4(BD2) and STAT6 inhibitors, toward IND-enabling studies.